Actinium Pharmaceuticals, Inc
Veridion Score
Composite trend over time
Why is ATNM moving today?
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ATNM.
ATNM insider activity
Actinium Pharmaceuticals, Inc
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ATNM.
ATNM contract awards, year to date.
Public federal awards linked to this ticker.
ATNM lobbying filings, year to date.
Registered lobbying filings matched to Actinium Pharmaceuticals, Inc.